ArticleJournal of clinical hypertension (Greenwich, Conn.)2011
Combination therapy in hypertension.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.Drugs in R&D · 2013Trial
- A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.American journal of therapeuticsTrial
- Too much, too soon? The argument against initial combination therapy in stage I hypertension.Journal of human hypertension · 2026Review
- Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects.Clinical drug investigation · 2026Article
- Trends in first-line monotherapy and combination therapy for hypertension in UK primary care.British journal of clinical pharmacology · 2026Article
- From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension.Clinical hypertension · 2026Review
- Multivariate Joint Analysis of Blood Pressure Measurements and Time to Remission: A Case Study of Hypertensive Patients Receiving Treatment at Jimma University Medical Center.Journal of research in health sciences · 2025Article
- Addressing Health Disparities in Hypertension: A Comprehensive Medical Elective and Survey Study Among Medical Students and Professionals.Medical science educator · 2024Article
- A network-based trans-omics approach for predicting synergistic drug combinations.Communications medicine · 2024Article
- Permanently Charged Cationic Lipids-Evolution from Excipients to Therapeutic Lipids.Small science · 2024Article
- Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records.Journal of the American Heart Association · 2024Article
- A retrospective cohort study of a community-based primary care program's effects on pharmacotherapy quality in low-income Peruvians with type 2 diabetes and hypertension.PLOS global public health · 2024Article
- Potential application of bisoprolol derivative compounds as antihypertensive drugs: synthesis andRoyal Society open science · 2023Article
- Government-Expert Joint Intervention with Treatment Algorithm and Improved Hypertension Management and Reduced Stroke Mortality in a Primary-Care Setting.International journal of hypertension · 2021Article
- Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.Hypertension (Dallas, Tex. : 1979) · 2020Article
- Review of Clinical Trials on the Effects of Tai Chi Practice on Primary Hypertension: The Current State of Study Design and Quality Control.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH).Frontiers in cardiovascular medicine · 2020Article
- Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research Datalink.Pharmacoepidemiology and drug safety · 2019Observational
- Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.Heart failure reviews · 2019Review
- Correlation of cardiomyocyte apoptosis with duration of hypertension, severity of hypertension and caspase-3 expression in hypertensive rats.Experimental and therapeutic medicine · 2019Article
Corrections and comments
- Reprint of
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points, including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single-pill (fixed) drug combinations and the implications of recent clinical trials involving specific combination strategies will also be discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.